| Trial ID: | L4288 |
| Source ID: | NCT00194896
|
| Associated Drug: |
Rosiglitazone
|
| Title: |
Preferred Treatment of Type 1.5 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00194896/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: rosiglitazone|DRUG: glyburide
|
| Outcome Measures: |
Primary: Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months., Changes in beta cell function assessed by fasting and stimulated C-peptide measured at 36 months., 36 months | Secondary: Patients Positive for T Cell Responses to Islet Proteins at 36 Months., Number of participants positive for T cell reactivity to islet proteins at 36 months., 36 months
|
| Sponsor/Collaborators: |
Sponsor: University of Washington | Collaborators: Seattle Institute for Biomedical and Clinical Research|GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
64
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2000-02
|
| Completion Date: |
2008-12
|
| Results First Posted: |
2011-08-10
|
| Last Update Posted: |
2018-03-29
|
| Locations: |
DVA Puget Sound Health Care System, Seattle, Washington, 98108, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00194896
|
